Actively Recruiting
Study of Qudexy XR Capsules to Prevent Migraine in Children Aged 6 to 11 Years Randomized, Double-Blind, Placebo-Controlled Phase 4 Trial
Led by Upsher-Smith Laboratories · Updated on 2025-01-27
132
Participants Needed
15
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating Qudexy XR, an extended-release capsule, for preventing migraines in children aged 6 to 11 years who have a history of migraine headaches. This Phase 4 trial aims to study the safety and effectiveness of Qudexy XR in reducing the monthly number of headache days compared to a placebo. The study is randomized, double-blind, and placebo-controlled to ensure reliable results. Participants will be randomly assigned to receive either Qudexy XR or matching placebo capsules during the 8-week maintenance period following a 28-day run-in period. The study includes careful monitoring of headache days through a diary. The trial uses a parallel-group design and maintains quadruple masking to keep participants, caregivers, investigators, and assessors unaware of treatment assignments. During the study, children will be assessed for changes in headache frequency using diaries and the Pediatric Migraine Disability Assessment Scale PedMIDAS. Safety and treatment effects will be monitored throughout the 16-week study duration. Participants need to meet specific criteria regarding age, weight, migraine history, and current treatments. The studys main outcome measure is the change in monthly headache days compared to baseline.
CONDITIONS
Brief Title
Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old
Research Team
P
PPD Laboratories
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here